Pay in 4 interest-free payments of $6.20 Learn more
Ships within 48 hours · Estimated delivery Sep 3 - Sep 8
BSO, or other drugs targeting GCLC, is a candidate drug for GCs with high ACTL6A expression
Y.Ming-YeoS
Alternative repletion strategies have focused on oral administration of GSH precursors (e.g., cysteine and glycine supplementation 9 ), and intravenous administration of GSH, 10 which although promising, is invasive and inconvenient, and therefore unlikely to be a practical solution
There are also legal considerations because neither peptide is FDA-approved for human use in this manner
US$ 26.38
,aspect=ignore)
US$ 24.13
US$ 21.37
